Sweden's Newbury Pharmaceuticals Q3 revenue rises on portfolio expansion

Newbury Pharmaceuticals AB

08/07/2026 07:09

Overview
Sweden specialty pharma firm's fiscal Q3 revenue rose 34% yr/yr
EBITDA loss for fiscal Q3 narrowed from a year earlier
Company secured generic approval for Palbociclib and extended loan facility to SEK 30 mln

Outlook
Company expects final quarter to benefit from additional product launches and tender activity
Newbury targets more than 30 launched products in Nordics by end-2026, subject to approvals
Company expects expanding portfolio and improving gross margins to offset fixed costs

Result Drivers
TENDER-DRIVEN SALES - Co said quarterly sales reflected variability of tender-driven demand in Nordic markets
PORTFOLIO EXPANSION - Revenue growth supported by expanding product portfolio and new product launches
HIGHER COST OF GOODS SOLD - Increased costs mainly driven by cost of goods sold rising with higher sales volumes

Company press release: ID:nMFN7CgVYc

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EBITDA
 
-SEK 4 mln
 

Analyst Coverage
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 2 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)